Aikaterini Tsantikidi, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, George Kapetsis, Georgios Tsaousis, Angeliki Meintani, Chrysiida Florou-Chatzigiannidou, Maria Gazouli, Christos Papadimitriou, Eleni Timotheadou, Athanasios Kotsakis, Anastasios Boutis, Ioannis Boukovinas, Eleftherios Kampletsas, Loukas Kontovinis, Elena Fountzilas, Charalampos Andreadis, Charisios Karanikiotis, Dimitrios Filippou, Georgios Theodoropoulos, Mustafa Özdoğan, George Nasioulas
Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The BRCA1/2 genes and mutations in many additional genes involved in the HR pathway may be responsible for the HRD phenomenon. The aim of the present study was to investigate the association between genomic loss of heterozygosity (gLOH) and alterations in 513 genes with targeted and immuno-oncology therapies in 406 samples using an NGS assay...
September 15, 2023: Diagnostics